About: Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
Creator	Ishii, Yui Iwasawa, Takahiro Kamimura, Hiroteru Kimura, Naruhiro Kojima, Yuichi Koseki, Youhei Kumagai, Masaru Motegi, Satoko Natsui, Kazuki Sato, Takeki Takamura, Masaaki Takeda, Nobutaka Takeuchi, Suguru Terai, Shuji Tominaga, Kentaro Tomiyoshi, Kei Tsuchiya, Atsunori Watanabe, Yusuke Yoshida, Yuki Yamazaki, Fusako
Source	Medline; PMC
abstract	The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions and must be mitigated or resolved as soon as possible. Mesenchymal stem cells (MSCs) and their exosomes can affect immune cells by inducing anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells, and can inactivate T cells. Hence, they are potential candidate agents for treatment of severe cases of COVID-19. In this review, we report the background of severe cases of COVID-19, basic aspects and mechanisms of action of MSCs and their exosomes, and discuss basic and clinical studies based on MSCs and exosomes for influenza-induced ARDS. Finally, we report the potential of MSC and exosome therapy in severe cases of COVID-19 in recently initiated or planned clinical trials of MSCs (33 trials) and exosomes (1 trial) registered in 13 countries on ClinicalTrials.gov.
has issue date	2020-06-22(xsd:dateTime)
bibo:doi	10.1186/s41232-020-00121-y
bibo:pmid	32582401
has license	cc-by
sha1sum (hex)	4682c945ebaf4b8e8f949b43a3a9dc8c31cecaeb
schema:url	https://doi.org/10.1186/s41232-020-00121-y
resource representing a document's title	Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
has PubMed Central identifier	PMC7306412
has PubMed identifier	32582401
schema:publication	Inflamm Regen
resource representing a document's body	covid:4682c945ebaf4b8e8f949b43a3a9dc8c31cecaeb#body_text
is schema:about of	named entity 'exosomes' named entity 'inducing' named entity 'activity' named entity 'healthcare' named entity 'clinical trials' named entity 'COVID-19' named entity 'DENDRITIC CELLS' named entity 'CANDIDATE' named entity 'CLINICAL TRIALS' named entity 'B CELLS' named entity 'AS SOON AS POSSIBLE' covid:arg/4682c945ebaf4b8e8f949b43a3a9dc8c31cecaeb named entity 'mitigated' named entity 'MSCs' named entity 'T cells' named entity 'ARDS' named entity 'severe' named entity 'conditions' named entity 'Mesenchymal stem cells' named entity 'cases' named entity 'causative agent' named entity 'exosomes' named entity 'coronavirus' named entity 'mechanisms of action' named entity 'MSCs' named entity 'exosomes' named entity 'MSCs' named entity 'coronavirus disease 2019' named entity 'virus' named entity 'exosomes' named entity 'exosomes' named entity 'ARDS' named entity 'ARDS' named entity 'CD4' named entity 'extracellular vesicles' named entity 'IL-6 receptor' named entity 'COVID' named entity 'ARDS' named entity 'incubation period' named entity 'gastrointestinal' named entity 'MHC' named entity 'ferritin' named entity 'COVID' named entity 'WHO' named entity 'pneumonia' named entity 'experimental group' named entity 'H7N9' named entity 'MERS' named entity 'hemophagocytic lymphohistiocytosis' named entity 'CRS' named entity 'diabetes mellitus' named entity 'virus' named entity 'osteoblasts' named entity '1, 2' named entity 'CD34' named entity 'ClinicalTrials.gov' named entity 'total bilirubin' named entity 'influenza' named entity 'COVID' named entity 'cytokine storm' named entity 'allogeneic' named entity 'therapeutic target'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software